Katz Laurence B, Aparicio Maria, Cameron Hilary, Ceppa Frederico
LifeScan Global Corporation, Malvern, PA.
La Comunidad Hispana, Kennett Square, PA.
Diabetes Spectr. 2022 Feb 15;35(1):86-94. doi: 10.2337/ds20-0101. Epub 2022 Feb 8.
To demonstrate the clinical value of OneTouch (OT) Verio Flex glucose meter used in combination with a Spanish-language version of the OT Reveal mobile application (app) to support diabetes care and improve glycemic control in an underserved Hispanic population with type 2 diabetes.
Test subjects ( = 81) used the meter and app for 12 weeks, while a randomized control group ( = 39) used their own glucose meters without connection to an app. Thereafter, test subjects continued the same regimen for an additional 12 weeks to determine the durability of effect, and control subjects crossed over to use the new meter and app.
Test subjects experienced a mean reduction in A1C of 1.0% after 12 weeks ( <0.001), a statistically significant greater reduction than in control subjects ( = 0.045). The improvement in A1C in test subjects was sustained over the next 12 weeks. Crossed-over subjects also demonstrated significant improvements in A1C ( <0.001). Mean blood glucose was reduced significantly without an increase in hypoglycemia, and results in range increased over 12 weeks of meter and mobile app use. Results were independent of subjects' numeracy skills. Subjects using the new meter and app reacted favorably to the tools and expressed improvements in their diabetes treatment satisfaction based on Diabetes Treatment Satisfaction Questionnaire-Change scores.
Use of the OT meter and a Spanish-language version of its diabetes management app in an underserved population helped participants achieve a sustained improvement in glycemic control. The tools were well received by the subjects and may have important utility in other low-numeracy, low-literacy populations.
证明OneTouch(OT)Verio Flex血糖仪与西班牙语版OT Reveal移动应用程序(应用)结合使用,在服务不足的西班牙裔2型糖尿病患者群体中支持糖尿病护理并改善血糖控制的临床价值。
测试对象(n = 81)使用血糖仪和应用程序12周,而随机对照组(n = 39)使用他们自己的血糖仪且不连接应用程序。此后,测试对象继续相同方案另外12周以确定效果的持续性,而对照对象转而使用新的血糖仪和应用程序。
12周后,测试对象的糖化血红蛋白(A1C)平均降低1.0%(P<0.001),与对照对象相比,降低幅度在统计学上显著更大(P = 0.045)。测试对象A1C的改善在接下来的12周内持续存在。转而使用新设备的对象的A1C也有显著改善(P<0.001)。平均血糖显著降低且低血糖情况未增加,在使用血糖仪和移动应用程序的12周内,血糖处于正常范围的时间增加。结果与受试者的计算能力无关。使用新血糖仪和应用程序的受试者对这些工具反应良好,并基于糖尿病治疗满意度问卷变化得分表示其糖尿病治疗满意度有所提高。
在服务不足的人群中使用OT血糖仪及其西班牙语版糖尿病管理应用程序有助于参与者实现血糖控制的持续改善。这些工具受到受试者的好评,可能在其他计算能力低、识字能力低的人群中具有重要用途。